![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Jubilant Biosys announced a new integrated drug discovery collaboration with Sanofi in the CNS therapeutic area.
The first collaboration with Sanofi started in 2016, to discover and develop small molecule inhibitors for multiple targets in the metabolic disorders therapeutic area.
The new research collaboration is aimed at discovering therapeutic small molecules that will address unmet needs in neurological diseases. Jubilant Biosys shall provide Sanofi drug discovery services utilizing its integrated drug discovery platform to identify lead candidates.
“We are delighted and privileged to have been selected again by a major pharmaceutical company such as Sanofi to help bring new innovation to the clinic,” Marcel Velterop, President, Jubilant Drug Discovery Services and CDMO, said. “This achievement is a testimony to the high-quality science and capability which Jubilant has built over the past decade. It fits well with our growth strategy and we are committed to expand our world-class integrated drug discovery capabilities.”
“We are looking forward to collaborating further with Jubilant. This new collaboration demonstrates Sanofi’s commitment to working to discover new medicines that target neurological diseases with high unmet need around the globe,” Rita Balice-Gordon, Global Head of Rare and Neurologic Diseases Therapeutic Area, said.
About Jubilant Biosys Limited
Jubilant Biosys, a subsidiary of Jubilant Life Sciences Ltd, an integrated global pharmaceutical and life sciences company, has presence in Bengaluru and Noida in India. Jubilant Biosys has demonstrated expertise in multiple therapeutic areas, including but not limited to Oncology, Metabolic Disorders, Pain & Inflammation and CNS. The business model includes both functional as well as integrated discovery services upto IND including GLP and GMP services, proprietary in-house innovation and strategic investments as the core components, which are available for collaborative research, partnership and out-licensing.
